- Home
- » Tags
- » Portola Pharmaceuticals
Top View
- Competitive Outlook Takes Its Toll on Merck and Portola's Factor Xa Inhibitor
- United States Securities and Exchange Commission Washington, D.C
- BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant As Specified in Its Charter) ______
- Portola Signs $120 Million-Worth Licensing Deals with Japanese Pharma Majors
- Alexion Completes Acquisition of Portola
- Meeting the Challenges of Direct-Acting Oral Anticoagulant Usage in Federal Medicine B:16” T:15.75” S:14.75”
- (SBN 165755) Daniel E. Barenbaum (SBN 209261) Jeffrey V
- CANADA (Class Action) SUPERIOR COURT PROVINCE of QUEBEC ______DISTRICT of MONTREAL DIANE GAGNON NO: 500-06-000732-152 Petitioner -Vs
- 20200915 MED-Project Participant List.Xlsx
- Portola 2015
- IPO Flurry Raises Valuation Gap Questions
- Avelumab (Anti-PD-L1)
- United States Securities and Exchange Commission Washington, D.C
- 2020-2021 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated
- Know the New: 2018 Novel Drug Approvals
- Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
- Rebateable Manufacturers
- Novartis-20-F-2011.87184950.Pdf
- Portola and Lee's Pharmaceutical Enter Into Agreement to Expand
- Presseinformation Portola, Bristol-Myers Squibb Und Pfizer
- Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009
- Joseph Post, Et Al. V. Portola Pharmaceuticals, Inc., Et Al. 20-CV
- Portola and Boehringer Lead Bleeding Antidote Charge
- Review of Andexanet Alfa: New Reversal Agent for the New Oral Anticoagulants
- Adis R&D Insight
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
- ANNEXA™-R Part 2: a Phase 3 Randomized, Double-Blind, Placebo
- Portola 16-508 SAP Draft
- ANDEXXA Pharmacologic Class Formulation(S), Including Intravenous Injection Adjuvants, Etc
- Andexxa® Makes a Splash! Current Trends in Anticoagulation Reversal